Launching a new generation of pharmacological solutions that target the root cause of diseases by restoring immune system homeostasis.
Reven Among Companies Expected to Boost Hypoxia Market
RJX by Reven
RJX is a stand-alone drug and a flexible formulation developed with a proprietary process to target areas of immunologic function without the need for stabilizers and preservatives.
“Our goal is to impact multiple disease indications stemming from inflammation ranging from cancer to cardiovascular disease in the same way antibiotics impacted infectious disease when they were discovered nearly a century ago.”
Michael Volk / Co-Founder & CSO
Reven Holdings, Inc. 2921 W. 120th Ave / Suite 220 Westminster, CO 80234
1-866-REVEN-RX (1-866-738-3679) firstname.lastname@example.org
© 2021 Reven Holdings, Inc. — All rights reserved.